Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In
J&J Might Have More To Offer For Coronavirus Than Biotechs
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
You may also be interested in...
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
The mRNA specialist outlined ambitious plans to bring a vaccine for cytomegalovirus to market during an R&D day after releasing positive Phase I data.
ACAM2000 gained unanimous support of FDA’s Vaccines and Related Biological Products Advisory Committee in May.